Kanagawa, Japan

Takuya Tashiro




Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Yokohama, JP (2012)
  • Kanagawa, JP (2012 - 2014)
  • Wako, JP (2016)

Company Filing History:


Years Active: 2012-2016

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Takuya Tashiro: Innovator in Glycolipid Research

Introduction

Takuya Tashiro is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of compounds with potential therapeutic applications. With a total of 8 patents, Takuya's work focuses on innovative solutions for medical challenges.

Latest Patents

Among his latest patents is the invention of a carbamate glycolipid, which serves as an effective antitumor active agent or vaccine adjuvant. This invention not only provides a novel compound but also outlines production methods and a medicament containing this compound. Another notable patent is the hydroxylated KRN7000 analogue, which offers a method for treating autoimmune diseases or suppressing immunity through the administration of the compound or its salts.

Career Highlights

Takuya Tashiro is affiliated with Riken Corporation, a leading research institution in Japan. His work at Riken has allowed him to explore various innovative avenues in the field of glycolipid research. His contributions have been instrumental in advancing the understanding of compounds that can be utilized in medical treatments.

Collaborations

Takuya has collaborated with esteemed colleagues such as Kenji Mori and Masaru Taniguchi. These partnerships have fostered a collaborative environment that enhances the research and development of groundbreaking inventions.

Conclusion

Takuya Tashiro's innovative work in glycolipid research exemplifies the impact of dedicated inventors in the medical field. His patents reflect a commitment to advancing therapeutic solutions that can benefit society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…